This content is only available within our institutional offering.
14 Nov 2018
Rude Health - finnCap Life Sciences quarterly sector note
Bioventix Plc (BVXP:LON), 4,600 | Byotrol plc (BYOT:LON), 0.1 | Inspiration Healthcare Group PLC (IHC:LON), 29.0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.2 | OptiBiotix Health PLC (OPTI:LON), 18.0 | SDI Group plc (SDI:LON), 56.0 | Synairgen plc (SNG:LON), 6.8 | Tristel Plc (TSTL:LON), 465
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Rude Health - finnCap Life Sciences quarterly sector note
Bioventix Plc (BVXP:LON), 4,600 | Byotrol plc (BYOT:LON), 0.1 | Inspiration Healthcare Group PLC (IHC:LON), 29.0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.2 | OptiBiotix Health PLC (OPTI:LON), 18.0 | SDI Group plc (SDI:LON), 56.0 | Synairgen plc (SNG:LON), 6.8 | Tristel Plc (TSTL:LON), 465
- Published:
14 Nov 2018 -
Author:
Mark Brewer -
Pages:
32
AIM Healthcare Index fell 10% in the past three months, compared with an 8.5% decline in the FT AIM All Share. The performance stats in the past month were more balanced, with AIM Health down 1.5% compared with a 3% decline in the AIM All Share. Despite this, ten finnLife 50 stocks showed positive gains with four rising by 15%+: namely Tiziana Life Sciences (+89% – FDA clearance to start Phase I trial with foralumab, an orally delivered antibody, and the announced intention to IPO on NASDAQ); Sinclair Pharma (+46% – agreed takeover); Omega Diagnostics (+28% – strategic update); and Creo Medical (+28% – product launch). Conversely, Diurnal shares fell c.80% on the back of a failed Phase III trial for Chronocort in chronic adrenal hyperplasia